| [1] Slamon DJ,Godolphin WA,Jones LA,et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J].Science,1989,244(4905):707-712.[2] Perez EA,Romond EH,Suman VJ,et al.Trastuzumab Plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer:planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J].J Clin Oncol,2014,32(33):3744-3752.[3] Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11):783-792.[4] van der Hage JA,van de Velde CJH,Julien JP,et al.Preoperative chemotherapy in primary operable breast cancer:Results from the European Organization for Research and Treatment of Cancer trial 10902[J].J Clin Oncol,2001,19(22):4224-4237.[5] Valachis A,Mauri D,Polyzos NP,et al.Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer:A systematic review and meta-analysis[J].Breast,2011,20(6):485-490.[6] Demonty G,Bernard-Marty C,Puglisi F,et al.Progress and new standards of care in the management of HER-2 positive breast cancer[J].Eur J Cancer,2007,43(3):497-509.[7] Buzdar AU,Ibrahim NK,Francis D,et al.Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer[J].J Clin Oncol,2005,23(16):3676-3685.[8] Chia SK.Neoadjuvant and adjuvant therapy for her2 positive disease[J].Am Soc Clin Oncol Educ Book,2015,35:e41-e48.[9] Buzdar AU,Valero V,Ibrahim NK,et al.Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil,epirubicin,and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer:An update of the initial randomized study population and data of additional patients treated with the same regimen[J].Clin Cancer Res,2007,13(1):228-233.[10] Gianni L,Eiermann W,Semiglazov V,et al.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer (the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet,2010,375(9712):377-384.[11] Gianni L,Eiermann W,Semiglazov V,et al.Follow-up results of NOAH,a randomized phase Ⅲ trial evaluating neoadjuvant chemotherapy with trastuzumab (CT plus H) followed by adjuvant H versus CT alone,in patients with HER2-positive locally advanced breast cancer[J].J Clin Oncol,2013,31(15):503.[12] Peintinger F,Buzdar AU,Kuerer HM,et al.Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab[J].Ann Oncol,2008,19(12):2020-2025.[13] Limentani SA,Brufsky AM,Erban JK,et al.Phase Ⅱ study of neoadjuvant docetaxel,vinorelbine,and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer[J].J Clin Oncol,2007,25(10):1232-1238.[14] Guarneri V,Broglio K,Kau SW,et al.Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors[J].J Clin Oncol,2006,24(7):1037-1044.[15] Gianni L,Eiermann W,Semiglazov V,et al.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH):follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet Oncol,2014,15(6):640-647.[16] Ogston KN,Miller ID,Payne S,et al.A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and survival[J].Breast,2003,12(5):320-327.[17] Chang HR.Trastuzumab-based neoadjuvant therapy in patients with her2-positive breast cancer[J].Cancer,2010,116(12):2856-2867.[18] 廖宁,张国淳,李学瑞,等.新辅助紫杉醇联合曲妥珠单抗在表皮生长因子受体2阳性可手术乳腺癌患者中的疗效及安全性评价[J].中华肿瘤杂志,2010,32(7):544-547.[19] 姚恒,赵玲,李索妮,等.紫杉醇脂质体对乳胶癌细胞SK-BR-3的放疗增敏作用及其机制[J].西安交通大学学报:医学版,2015,36(5):628-633.[20] 曹志宇,何建苗,杨波,等.局部晚期乳腺癌新辅助化疗联合保乳手术的临床疗效观察:附81例报告[J].解放军医学杂志,2015,40(6):488-491. |
